Table 3.
Drugs used in antiangiogenic therapy and immunotherapy.
| Therapy | Compounds | Application | Phase | NCT number | Improved survival time |
|---|---|---|---|---|---|
| Antiangiogenic therapy | Bevacizumab | Unresectable, locally advanced or recurrent non-squamous NSCLC | Approved | PFS: 4.4 months (186) | |
| Antiangiogenic therapy plus chemotherapy | Bevacizumab plus carboplatin and paclitaxel | Unresectable, locally advanced, recurrent or metastatic non-squamous NSCLC | Phase II | NCT00318136 | No results posted |
| Antiangiogenic therapy plus chemotherapy | Bevacizumab plus cisplatin and gemcitabine | Locally advanced, metastatic, or recurrent non-squamous NSCLC | Phase III | NCT00806923 | median OS>13 months |
| Antiangiogenic therapy plus Immunotherapy | Bevacizumab and atezolizumab | Non-squamous NSCLC patients with higher PD-L1 expression (≥50%) but without EGFR/ALK/ROS1 mutations | Phase II | NCT03836066 | Completion date: 30 January 2024 |
| Antiangiogenic therapy plus immunotherapy and chemotherapy | Bevacizumab combined with atezolizumab and chemotherapy (carboplatin and paclitaxel) | NSCLC patients with KRAS and STK11 mutations and/or STK11, KEAP1, TP53 mutations and/or high PD-L1 expression | Phase III | NCT02366143 | PFS: 29 months, OS: 53 months |
| Antiangiogenic therapy | FKB238, LY01008 | Non-squamous NSCLC | Phase III | NCT02810457, NCT03533127 | PFS: 30 months, OS: 30 months |
| Antiangiogenic therapy plus Immunotherapy | Anlotinib plus camrelizumab | Advanced NSCLC patients who are resistant to the first-line therapy | Phase IB | NCT04670107 | No results posted |
| Immunotherapy | Ipilimumab | Metastatic NSCLC with PD-L1 overexpression and no EFGR or ALK mutation | Approved | PFS: 0.84 years (169) | |
| Immunotherapy | Pembrolizumab, atezolizumab | Metastatic NSCLC with high PD-L1 expression (≥50%) and without EGF) or ALK mutation | Approved | mPFS: 10.3 months (170), median OS: 15.5 months (171) | |
| Immunotherapy | Nivolumab | Metastatic NSCLC with EGFR- or ALK-positive mutation | Approved | mPFS: 4.2 months, median OS: 14.4 months (172) | |
| Immunotherapy | Durvalumab | Unresectable stage III NSCLC after failed chemotherapy and radiotherapy | Phase III | NCT02395172 | PFS: 907 days, OS: 1,420 days |
| Immunotherapy | Avelumab | PD-L1 positive, NSCLC after a failed platinum-based doublet | Phase III | NCT02395172 | PFS: 907 days |
| Immunotherapy | Sugemalimab | Stage IV NSCLC | Phase III | NCT03789604 | Completion date: 31 August 2024 |
| Immunotherapy | Toripalimab | Limit-stage small cell lung cancer that has no reaction to the current chemotherapy | Phase III | NCT04418648 | Completion date: 31 May 2024 |
| Immunotherapy plus chemotherapy | Toripalimab plus platinum-based doublet chemotherapy | Stage III NSCLC | Phase II | NCT04304248 | Completion date: 30 July 2026 |
| Immunotherapy plus radiotherapy | Pembrolizumab plus radiotherapy | Metastatic NSCLC patients | Phase III | NCT02492568, NCT02444741 | Completion date: 17 September 2022 |
| Immunotherapy | Nivolumab plus ipilimumab | Stage IV NSCLC | Phase III | NCT02477826 | Completion date: 30 August 2024 |
| Immunotherapy | Durvalumab plus tremelimumab | Advanced NSCLC with resistance of PD-(L)1 therapy | Phase II | NCT03373760 | OS: 7 months |
| Immunotherapy plus radiotherapy | Durvalumab and/or tremelimumab plus radiotherapy | Metastatic or locally advanced NSCLC | Phase II | NCT05000710 | Completion date: December 2026 |
| Immunotherapy plus chemotherapy | Camrelizumab plus chemotherapy such as carboplatin and paclitaxel | Stage IV squamous NSCLC | Phase III | NCT03668496 | PFS: 9.1 months, median OS: 18.2 months |
| Immunotherapy plus chemotherapy | Camrelizumab and chemotherapy including carboplatin and pemetrexed | NSCLC patients without EGFR and ALK mutations | Phase III | NCT03134872 | mPFS: 11 months |
| Immunotherapy | Avelumab plus pepinemab | Advanced NSCLC | Phase Ib/II | NCT03268057 | mPFS: 8.4 weeks |